相关临床试验
242
34 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
5
2.1%
已完成
78
32.2%
Enrolling By Invitation
4
1.6%
尚未招募
25
10.3%
招募中
39
16.1%
终止
1
0.4%
Unknown
88
36.4%
撤回
2
0.8%
暂无批准数据
- A phase 2 trial demonstrated that neoadjuvant short-course radiotherapy followed by camrelizumab and CAPOX chemotherapy achieved an 80.2% three-year disease-free survival rate in locally advanced rectal cancer patients. - The treatment regimen showed particular promise in microsatellite-stable patients, who comprised 93.3% of the study population and typically have limited immunotherapy options. - Patients achieving pathological complete response had superior outcomes, with 100% three-year disease-free survival compared to 63.5% in non-responders. - The combination therapy maintained a favorable safety profile with no grade 5 adverse events or emergent toxicities observed during long-term follow-up.
- Chinese scientists achieved a breakthrough by maintaining a gene-edited pig kidney's function in a macaque for 184 days, marking progress in xenotransplantation. - The pig kidney, modified with four gene edits, functioned normally for five months in the macaque before chronic rejection began. - Researchers used an improved immunosuppressive regimen to extend graft survival, aiming to pave the way for human clinical trials. - This milestone brings China closer to international standards in xenotransplantation research, addressing the critical need for organ donors.
